Leukaemia (Rapid Acute) DNA and RNA NGS Panel

Requires patient informed consent

Sample Reqs

Aor bone marrow aspirate sample

Turnaround

3 days

Special instructions

No special instructions.

Sample type guide

Lavender Vacutainer, EDTA anticoagulant, 3ml minimum

Test details

This next-generation sequencing (NGS) panel, with a turnaround time of 3 days, enables the rapid analysis of key DNA and RNA targets where the speed of result is essential to guide therapy for acute leukaemia cases.

The panel can simultaneously interrogate 45 DNA target genes and 30 RNA fusion driver genes (see below). A comprehensive profile of myeloid mutations can be produced from a single NGS run; over 700 unique fusion transcripts can be sequenced.

Gene content on the panel has been curated to cover relevant targets for all the major myeloid disorders – acute myeloid leukaemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPNs), chronic myeloid leukaemia (CML), chronic myelomonocytic leukaemia (CMML), and juvenile myelomonocytic leukaemia (JMML). Among the targets are Calreticulin (CALR), JAK2, MPL and NPM1, which were previously offered as individual tests.

DNA Panel (45 genes)
DNA – 28 hotspot genes	ANKRD26, ABL1, BRAF, CBL, CSF3R, DDX41, DNMT3A, FLT3 (ITD, TKD), GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, MYD88, NPM1, NRAS, PPM1D, PTPN11, SMC1A, SMC3, SETBP1, SF3B1, SRSF2, U2AF1, WT1.
DNA - 17 full genes	ASXL1, PRPF8, BCOR, RB1, CALR, RUNX1, CEBPA, SH2B3, ETV6, STAG2, EZH2, TET2, IKZF1, TP53, NF1, ZRSR, PHF6.
DNA – 5 expression genes	BAALC, MECOM, MYC, SMC1A, WT1.
DNA – 5 expression control genes	EIF2B1, FBXW2, PSMB2, PUM1, TRIM27.

RNA panel (30 genes)
RNA –30 fusion driver genes	ABL1, ALK, BCL2, BRAF, CCND1, CREBBP, EGFR, MLLT10, ETV6, FGFR1, FGFR2, FUS, HMGA2, JAK2, KMT2A, (MLL PDTs), MECOM, MET, MLLT3, MYBL1, MYH11, NTRK3, NUP98 NUP214 PDGFRA PDGFRB RARA RBM15 RUNX1 TCF3 TFE

Additional information

Last-updated: 13/03/23

Back to test list